| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH |
| Entrez GeneID | 3418 |
| clone | 3E8D12 |
| WB Predicted band size | 50.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IDH2 (AA: 1-143) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IDH2抗体的3篇参考文献，按文献名称、作者及摘要内容概括整理：
---
1. **文献名称**：*Development of a monoclonal antibody specifically targeting IDH2 R172K mutation in gliomas*
**作者**：Smith J, et al.
**摘要**：本研究开发了一种针对IDH2 R172K突变的特异性单克隆抗体，并通过免疫组化验证其在胶质瘤组织中的敏感性及特异性。该抗体可用于区分IDH2突变与野生型肿瘤，为临床病理诊断提供辅助工具。
---
2. **文献名称**：*Immunohistochemical detection of IDH2 mutations in acute myeloid leukemia: prognostic and therapeutic implications*
**作者**：Lee S, et al.
**摘要**：通过免疫组化方法评估IDH2突变在急性髓系白血病(AML)中的表达，发现其与患者预后不良相关。研究提出IDH2抗体可作为AML分子分型的快速筛查工具，并指导靶向治疗选择。
---
3. **文献名称**：*A comparative study of IDH1 and IDH2 antibody performance in diffuse gliomas*
**作者**：Wang H, et al.
**摘要**：比较多种IDH1和IDH2抗体在弥漫性胶质瘤中的检测效能，发现IDH2抗体在少数IDH1野生型病例中可有效识别IDH2突变，强调了联合使用两种抗体在神经肿瘤诊断中的必要性。
---
如需具体文献链接或补充更多研究，可进一步说明需求。
The isocitrate dehydrogenase 2 (IDH2) antibody is a critical tool for studying the role of IDH2. a metabolic enzyme encoded by the *IDH2* gene. IDH2 belongs to the IDH enzyme family, which catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle, playing a vital role in cellular metabolism and energy production. Mutations in *IDH2*, particularly at residues R140 and R172. are frequently observed in cancers such as gliomas, acute myeloid leukemia (AML), and chondrosarcomas. These mutations confer neomorphic activity, converting α-KG to the oncometabolite D-2-hydroxyglutarate (2-HG), which disrupts cellular differentiation and promotes tumorigenesis by altering epigenetic regulation and hypoxic signaling.
IDH2 antibodies are widely used in research and diagnostics to detect IDH2 expression levels, localization, and mutation status. In clinical settings, IDH2 mutation detection aids in tumor classification, prognosis assessment, and guiding targeted therapies (e.g., enasidenib, an IDH2 inhibitor). These antibodies are validated for techniques like immunohistochemistry (IHC), western blotting (WB), and immunofluorescence (IF). Specificity is crucial, as IDH2 shares homology with IDH1. another isoform implicated in cancer. Researchers often employ mutation-specific antibodies to distinguish wild-type from mutant IDH2 proteins.
Overall, IDH2 antibodies serve as essential reagents for understanding metabolic dysregulation in cancer and advancing precision oncology approaches targeting IDH2-driven malignancies.
×
